最新指南解读:起始注射治疗的选择?  

Interpretation of the Latest Guidelines:the Choice of Initial Antihyperglycemic Injection Therapy

作　　者：周岩 姬秋和 ZHOU Yan;JI Qiu-he(Department of Endocrinology,Xi'an International Medical Center Hospital,Xi'an Shanxi 710100,China;Department of Endocrinology,Xijing Hospital,Air Force Military Medical University,Xi'an Shanxi 710032,China)

机构地区：[1]西安国际医学中心医院内分泌代谢科,陕西西安710100 [2]空军军医大学西京医院内分泌科,陕西西安710032

出　　处：《药品评价》2020年第S01期19-22,共4页Drug Evaluation

摘　　要：2型糖尿病控制现状不佳的一个很重要的原因是治疗强化的推迟,也就是“临床惰性”,尤以注射降糖治疗的推迟为著。胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonists,GLP-1 RA)作为一类新型注射用降糖药,克服了胰岛素制剂增加低血糖风险和体重的一些不良作用,有利于解除对注射降糖治疗的顾虑,推动早期注射治疗强化,且在最新临床指南中已获得较胰岛素制剂更为优先的治疗地位,在改善血糖控制和糖尿病预后方面的表现值得期待。The delay of treatment intensification which is so called"clinical inertia"is one of the main reasons for the poor control of type 2 diabetes.The delay of antihyperglycemic injection therapy is especially prominent.GLP-1 receptor agonists,as a new class of antihyperglycemic injection therapy,overcome the adverse effects such as hypoglycemia and increasing body weight of insulin preparations.They are helpful for alleviating concerns about antihyperglycemic injection therapy,and promoting the early intensification of injection therapy.In the latest clinical guidelines,GLP-1 receptor agonists have been given a higher priority than insulin preparations,and their performance in improving blood glucose control and diabetes prognosis is worth looking forward to.

关 键 词：2型糖尿病 临床惰性 治疗惰性 治疗强化 胰高糖素样肽-1受体激动剂 基础胰岛素 

分 类 号：R587.1[医药卫生—内分泌]